Search This Blog

Wednesday, November 30, 2022

Clover-Dynavax Vaccine Candidate Reduced Household Transmission of SARS-CoV-2

  The study, a collaboration between Clover and the International Vaccine Institute, showed that a household contact was 84% less likely to get a SARS-CoV-2 infection when the infected household member had received SCB-2019 (CpG 1018/Alum) compared to placebo --

-- Results indicate that vaccination with SCB-2019 can potentially help control the spread of SARS-CoV-2 within communities through the reduction of transmission to household contacts and through previously demonstrated efficacy against SARS-CoV-2 --

-- SCB-2019 is among the first COVID-19 vaccines to demonstrate ability to significantly reduce SARS-CoV-2 transmission prospectively in a clinical study to date --

https://finance.yahoo.com/news/clover-vaccine-candidate-reduced-household-102800002.html

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.